The landscape of the American cannabis industry has reached a historic turning point. Thursday, April 23 the Trump administration officially announced the reclassification of medical marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Acting Attorney General Todd Blanche signed the order this morning, executing a directive from President Trump’s December 2025 Executive Order. For cannabis operators, this is not merely a symbolic victory; it is a fundamental shift in the financial and regulatory gravity of the industry.
The Most Significant Change: Section 280E Relief
For years, the single greatest hurdle to profitability in the cannabis sector has been Internal Revenue Code Section 280E. This provision prohibited businesses dealing in Schedule I or II substances from deducting ordinary business expenses—such as rent, payroll, and marketing—from their federal taxes.
With the move to Schedule III, Section 280E no longer applies.
What this means for your bottom line:
- Reduced Effective Tax Rates: Many operators currently face effective federal tax rates of 70% or higher. Under Schedule III, cannabis businesses will be taxed like standard corporations, typically around 21% to 28%.
- Immediate Cash Flow Injection: Estimates suggest this change will unlock billions in after-tax cash flow across the industry.
- Revised Entity Structures: The complex, multi-tiered organizational structures many businesses used to mitigate 280E may no longer be necessary.
What Rescheduling Is (And Is Not)
It is critical to distinguish between rescheduling and legalization. While this move acknowledges the medical utility of cannabis, it does not create a federal “free-for-all.”
| Feature | Impact Under Schedule III |
| Federal Status | Remains a federally controlled substance, but at a lower risk tier (similar to ketamine or Tylenol with codeine). |
| Interstate Commerce | Still generally prohibited. State-legal programs remain isolated by state lines for now. |
| Banking | Expected to improve. While not a replacement for the SAFER Banking Act, Schedule III reduces the “reputational risk” for major financial institutions. |
| FDA Oversight | Likely to increase. Schedule III substances are subject to higher levels of federal oversight regarding manufacturing and labeling standards. |
Strategic Considerations for 2026
The transition to Schedule III is an “event-driven” planning moment. At HBK, we are advising our clients to focus on the following areas immediately:
- Tax Planning & Amended Returns: We must evaluate the effective date of the rescheduling to determine if refund claims or amended returns for the 2025/2026 tax years are viable.
- Accounting Method Changes: Moving away from 280E requires a shift in how you track inventory and overhead. Modernizing your accounting systems now is vital to ensure compliance with standard GAAP and IRC rules.
- Audit Readiness: Increased profitability often brings increased scrutiny. As more traditional capital enters the space, having “audit-ready” financials becomes a prerequisite for growth and M&A activity.
- State-Level Impacts: Be mindful of state-specific changes. For example, in Michigan, businesses are navigating a new 24% wholesale excise tax effective January 1, 2026. Rescheduling relief at the federal level must be balanced against evolving state tax burdens.
The Path Forward
This move signals that the federal government is finally aligning with the reality of state-legal markets. However, the regulatory “dust” has not yet settled. Litigation from opponents and further rulemaking by the DEA and DOJ are expected in the coming months.
Expert Insight: “The elimination of 280E is the ‘Great Normalization’ the industry has waited for. It transforms cannabis from a high-risk cash-and-carry business into a legitimate, scalable asset class.” — HBK Cannabis Solutions Team
If you have questions about how this rescheduling affects your specific tax position or corporate structure, please reach out to your HBK advisor.
Contact HBK Cannabis Solutions Our team specializes in helping cannabis operators navigate the complexities of tax, accounting, and strategic growth in this rapidly evolving environment.
How has your business’s cash flow projections changed in light of today’s Schedule III announcement?
As of this update, this information applies only to medical marijuana and does not extend to recreational use. Additional clarity is expected following the hearings scheduled for June 29.
"*" indicates required fields